These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38921800)

  • 1. Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials.
    Mankad VS; Leach A; Chang Y; Wählby Hamrén U; Kiazand A; Kubiak RJ; Takas T; Villafana T; Shroff M
    Pathogens; 2024 Jun; 13(6):. PubMed ID: 38921800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
    Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
    Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balanced on the Biggest Wave: Nirsevimab for Newborns.
    McPherson C; Lockowitz CR; Newland JG
    Neonatal Netw; 2024 Apr; 43(2):105-115. PubMed ID: 38599778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials.
    Ahani B; Tuffy KM; Aksyuk AA; Wilkins D; Abram ME; Dagan R; Domachowske JB; Guest JD; Ji H; Kushnir A; Leach A; Madhi SA; Mankad VS; Simões EAF; Sparklin B; Speer SD; Stanley AM; Tabor DE; Hamrén UW; Kelly EJ; Villafana T
    Nat Commun; 2023 Jul; 14(1):4347. PubMed ID: 37468530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
    Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
    N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
    Hammitt LL; Dagan R; Yuan Y; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Brooks D; Grenham A; Wählby Hamrén U; Mankad VS; Ren P; Takas T; Abram ME; Leach A; Griffin MP; Villafana T;
    N Engl J Med; 2022 Mar; 386(9):837-846. PubMed ID: 35235726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
    Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
    JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
    Francisco L; Cruz-Cañete M; Pérez C; Couceiro JA; Otheo E; Launes C; Rodrigo C; Jiménez AB; Llorente M; Montesdeoca A; Rumbao J; Calvo C; Frago S; Tagarro A
    An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
    Bergeron HC; Tripp RA
    Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.
    Dagan R; Hammitt LL; Seoane Nuñez B; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Chang Y; Currie A; Grenham A; Shroff M; Takas T; Mankad VS; Leach A; Villafana T
    J Pediatric Infect Dis Soc; 2024 Feb; 13(2):144-147. PubMed ID: 38219024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection.
    Brady T; Cayatte C; Roe TL; Speer SD; Ji H; Machiesky L; Zhang T; Wilkins D; Tuffy KM; Kelly EJ
    Front Immunol; 2023; 14():1283120. PubMed ID: 37901217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
    Drysdale SB; Cathie K; Flamein F; Knuf M; Collins AM; Hill HC; Kaiser F; Cohen R; Pinquier D; Felter CT; Vassilouthis NC; Jin J; Bangert M; Mari K; Nteene R; Wague S; Roberts M; Tissières P; Royal S; Faust SN;
    N Engl J Med; 2023 Dec; 389(26):2425-2435. PubMed ID: 38157500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nirsevimab: Expansion of Respiratory Syncytial Virus Prevention Options in Neonates, Infants, and At-Risk Young Children.
    Fly JH; Eiland LS; Stultz JS
    Ann Pharmacother; 2024 Apr; ():10600280241243357. PubMed ID: 38654469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
    Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS
    MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
    Cieslak CM
    Nurs Womens Health; 2024 Feb; 28(1):75-79. PubMed ID: 38070539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
    Hodgson D; Koltai M; Krauer F; Flasche S; Jit M; Atkins KE
    Vaccine; 2022 Nov; 40(49):7151-7157. PubMed ID: 36328884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
    Domachowske JB; Chang Y; Atanasova V; Cabañas F; Furuno K; Nguyen KA; Banu I; Kubiak RJ; Leach A; Mankad VS; Shroff M; Takas T; Villafana T; Wählby Hamrén U
    J Pediatric Infect Dis Soc; 2023 Aug; 12(8):477-480. PubMed ID: 37466917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.